Cerecor has announced it closed the first tranche of its Series B round of funding, which in total is expected to raise $32 million. The tranche brought in about $16.3 million according to SEC filings. Leading this tranche were New Enterprise Associates, Apple Tree Partners and MPM Capital. The proceeds will help the clinical stage biopharmaceutical company continue Phase 2 development of its lead candidate CERC-301, a once-a-day adjunctive therapy for severe major depressive disorder. The company raised over $6.8 million at a valuation just north of $72 million in a Series A-1 round last September.